Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.

The article discusses 2024 data which showed that blue light cystoscopy (BLC) is linked to improved outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) compared to white light cystoscopy (WLC). Topics covered include the comparatively lower recurrence risk and progression risk for patients following BLC, and the latter's improved overall survival. Also noted is improved tumor visualization's help in determining intravesical therapy use, such as Bacillus Calmette-Guerin (BCG).